Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment

被引：0
|
作者：
Van der Biji, AE
Breedveld, FC
Antoni, CE
Kalden, JR
Kary, S
Burmester, GR
Unnebrink, K
Kupper, H
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Univ Erlangen Nurnberg, Erlangen, Germany
[3] Charite Humbold Univ, Berlin, Germany
[4] Abbott GmbH Co KG, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：428 / +
页数：2
相关论文
共 50 条
  • [41] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
  • [42] Improved Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Failed Adalimumab or Placebo Treatment and Were Rescued with Baricitinib
    Fautrel, Bruno
    Taylor, Peter C.
    Michaud, Kaleb
    Patel, Himanshu
    Zhu, Baojin
    Gaich, Carol L.
    Guo, Jiaying
    Quebe, Amanda
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
    Bessette, Louis
    Khraishi, Majed
    Kivitz, Alan J.
    Kaliyaperumal, Arunan
    Grantab, Rama
    Poulin-Costello, Melanie
    Isaila, Maya
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] Adalimumab (HUMIRA®) is effective and well-tolerated in combination with traditional DMARDs in treating rheumatoid arthritis in real-life clinical practice.
    Ivorra, J. A. Román
    Valesini, G.
    Bijlsma, J. W. J.
    Unnebrink, K.
    Oezer, U.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S404 - S404
  • [45] Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis who Failed Adalimumab Treatment
    Khraishi, Majed
    Bessette, Louis
    Kivitz, Alan
    Kaliyaperumal, Arunan
    Grantab, Rana
    Poulin-Costello, Melanie
    Isaila, Maya
    Collier, David
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 947 - 947
  • [46] Adalimumab (Humira®) is effective in treating patients with psoriatic arthritis (PSA) in real-life clinical practice:: Results of the stereo trial
    van den Bosch, F.
    Manger, B.
    Goupille, P.
    McHugh, N.
    Roedevand, E.
    Holck, P.
    van Vollenhoven, R.
    Leirisalo-Repo, M.
    FitzGerald, O.
    Frank, C.
    Kron, M.
    Frank, M.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 98 - 98
  • [47] PRESENCE OF ANTIBODIES TO ADALIMUMAB AND INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL REMISSION
    Eng, G.
    Fana, V.
    Omerovic, E.
    Hojsgaard, P.
    Lindegaard, H. M.
    Jensen, E. K.
    Bouchelouche, P. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 230 - 230
  • [48] Infliximab, Etanercept, and Adalimumab switching in patients with rheumatoid arthritis in the CORRONA database
    Dabbous, O.
    Kremer, J.
    Rambharose, J.
    El Taha, M.
    Reed, G.
    Tang, B.
    Thomson, H.
    Domdey, A.
    Rahman, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 42 - 42
  • [49] Adalimumab (HUMIRA®) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice:: 12-week outcomes in the react trial
    Burmester, GR
    Saez, IM
    Malaise, MG
    da Silva, JC
    Webber, DG
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 423 - +
  • [50] Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S562 - S562
12345